*Compared to other leading comprehensive tissue tests. The “most advanced” referring to the first and only commercially available tissue test to deliver multiomic insights from a single input.
†92% less surface area, 2mm² for Guardant360 Tissue vs. 25mm² industry standard. When compared to the required sample input of other tissue testing companies. Comparisons are based on publicly available analytical specification information as of November 2025.
‡DNA only, when sample requirements are met. As of April 2026.
§With tissue input of ≥2mm² surface area and ≥5% tumor cellularity. Referring to DNA performance only; RNA performance may vary.

InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Important Note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.